24th week of 2009 patent applcation highlights part 46 |
Patent application number | Title | Published |
20090149376 | Pharmaceutical and Therapeutic Applications Relating to a Type 9 Adenylyl Cyclase Polymorphism in Asthma and Reversible Bronchial Obstruction - A pharmaceutical composition comprising an expression product of a Type Nine adenylyl cyclase gene polymorphism, along with a suitable physiological carrier, are provided. In addition, methods related to treating patients having asthma or a reversible bronchial obstruction, kits for determining the responsiveness of an individual to treatment regimens, and assays for screening pharmaceutical for efficacy in treatment are also provided. | 2009-06-11 |
20090149377 | METHODS FOR REGULATION OF p53 TRANSLATION AND FUNCTION - The present invention relates to novel methods for modulating the activity of p53 tumor suppressor protein by affecting p53 translational regulation. More specifically, the invention relates to novel methods for modulating p53 mRNA translation in a cell by affecting a function of a p53 5′-untranslated region (5′UTR), including its interaction with proteins such as Ribosomal Protein L26 (RPL26), nucleolin, and p53. The invention also relates to the use of these methods for treating cancer, neurodegenerative disorders and minimizing the negative effects of cellular stresses. | 2009-06-11 |
20090149378 | GLP-1 ANALOGUES - The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. | 2009-06-11 |
20090149379 | NOVEL USE OF CYTOKINE INHIBITORS - The present invention relates to a method for prevention or reduction of scar tissue and/or adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment. | 2009-06-11 |
20090149380 | VASOSTATIN AS MARROW PROTECTANT - Specific fragments of vasostatin are disclosed. These fragments are of use in methods of stimulating the proliferation or survival of a hematopoietic cell exposed to a chemotherapeutic agent or irradiation. Methods of stimulating the proliferation or survival of a hematopoietic cell using these fragments are also disclosed. In one embodiment, methods are disclosed for stimulating the growth or survival of a hematopoietic stem cell with a fragment of vasostatin, in the presence of a growth factor. | 2009-06-11 |
20090149381 | Methods of regulating angiogenesis through stabilization of PEDF - The invention provides methods of inhibiting angiogenesis within a tissue, promoting neuron protection within a tissue, and treating a disease in a mammal, wherein (a) a gene transfer vector encoding a protein of a serpin superfamily or a therapeutic fragment or variant thereof or (b) a protein of a serpin superfamily or a therapeutic fragment or variant thereof is administered with an inhibitor of matrix metalloprotease (MMP). Alternatively, the method comprises administration of (a) a protein of a serpin superfamily or therapeutic fragment or variant thereof or (b) a gene transfer vector encoding a protein of a serpin superfamily or a therapeutic fragment or variant thereof, wherein the protein or nucleic acid encoding the protein comprises at least one mutation which renders the protein of the serpin superfamily resistant to cleavage by an MMP. | 2009-06-11 |
20090149382 | Modulation of lipid rafts - The present invention relates to the use of an antisecretory protein, derivative, homologue, and/or fragment thereof, having equivalent activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of dysfunction, e.g. abnormal function, hypo- or hyper-function of lipid rafts, receptors and/or caveolae. A dysfunction of lipid rafts, receptors and/or caveolae may be caused by or be a cause of a variety of other conditions, which are also encompassed by the present invention, such as vascular, and lung dysfunctions, and/or endocrine disorders, e.g. diabetes and related disorders. Furthermore, the invention relates to a method for the treatment and/or prevention of dysfunction of lipid rafts and/or caveolae in a mammal in need thereof. | 2009-06-11 |
20090149383 | COMPOSITIONS AND METHODS FOR FACILITATING HEME-IRON EXPORT FROM CELLS - The invention provides a high affinity heme-binding agent, which can be provided in the form of a pharmaceutical composition that includes, optionally, a pharmaceutically acceptable carrier. The heme-binding agent can be used in a method of facilitating heme-iron export from a cell. The method comprises contacting a cell with a high affinity heme-binding agent. Also provided is a method of treating a disorder associated with excess iron in cells in a subject. The method comprises administering to the subject an effective amount of the composition of the invention. The subject is typically a mammal, most typically a human or veterinary subject. | 2009-06-11 |
20090149384 | Protection of Photoreceptors in Experimental Autoimmune Uveitis - Techniques are described for the administration of crystallins, e.g., αA and/or β crystallin, to protect retinal photoreceptors of subjects inoculated with Experimental Autoimmune Uveitis. The present disclosure provides a unique and novel approach to the prevention of photoreceptor degeneration in uveitis and other blinding diseases mediated by oxidative stress including retinitis pigmentosa, macular degeneration, diabetic retinopathy and glaucoma through the administration of crystalline, e.g., αA and/or β crystallin. | 2009-06-11 |
20090149385 | NEUREGULINS FOR PREVENTION AND TREATMENT OF DAMAGE FROM ACUTE ASSAULT ON VASCULAR AND NEURONAL TISSUE AND AS REGULATORS OF NEURONAL STEM CELL MIGRATION - Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement of stem cell migration from the ventricle to the site of injury to the brain. | 2009-06-11 |
20090149386 | NEUREGULINS FOR PREVENTION AND TREATMENT OF DAMAGE FROM ACUTE ASSAULT ON VASCULAR AND NEURONAL TISSUE AND AS REGULATORS OF NEURONAL STEM CELL MIGRATION - Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement of stem cell migration from the ventricle to the site of injury to the brain. | 2009-06-11 |
20090149387 | Use of GLP-1 Peptides - GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety. | 2009-06-11 |
20090149388 | DRIED BLOOD FACTOR COMPOSITION COMPRISING TREHALOSE - A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed. | 2009-06-11 |
20090149389 | Kinase Inhibitors And Uses Thereof - The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population. | 2009-06-11 |
20090149390 | OXIDANT RESISTANT APOLIPOPROTEIN A-1 AND MIMETIC PEPTIDES - A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation. | 2009-06-11 |
20090149391 | Novel antimicrobial bolisin peptides - The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites. | 2009-06-11 |
20090149393 | Novel Proteins Within The Type E Botulinum Neurotoxin Complex - The invention features a polypeptide complex synthesized by bacteria of the genus | 2009-06-11 |
20090149394 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES - The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o | 2009-06-11 |
20090149395 | NOVEL MACROCYCLIC POLYENE LACTAMS - The invention relates generally to novel macrocyclic polyene lactams and their analogs, to processes for the preparation of these novel macrocyclic polyene lactams, to pharmaceutical compositions comprising the novel macrocyclic polyene lactams; and to methods of using the novel macrocyclic polyene lactams to treat or inhibit various disorders. | 2009-06-11 |
20090149396 | DERIVATIVE OF GLUCOSE AND VITAMIN F, COMPOSITIONS COMPRISING IT, USES AND PREPARATION PROCESS - An O-acyl product derived from glucose which may be obtained by partial or total esterification of glucose and of vitamin F, comprising a mixture of esters, for example, monoesters, of glucose and of at least one acid chosen from linoleic acid, oleic acid, palmitic acid and stearic acid, compositions, for example, cosmetic and pharmaceutical compositions, comprising this novel derivative, and their use for improving the condition of head hair and/or other hairs, and, for example, for reducing and/or impeding the loss of head hair and/or other hairs, and/or for inducing and/or stimulating hair growth, as well as a process for preparing O-acyl derivatives mainly in position 6 of glucose, comprising preparing a mixed anhydride by reacting a carboxylic acid with a trimethylacetyl halide, followed by reacting said mixed anhydride formed with glucose. | 2009-06-11 |
20090149397 | TREATMENT OF CANCER WITH COMBINATIONS OF TOPOISOMERASE INHIBITORS AND PARP INHIBITORS - In one aspect, the present invention provides a composition and a kit comprising a combination of topoisomerase inhibitor and PARP inhibitor for treatment of cancer. In another aspect, the invention provides a method of treating cancer comprising administering to a subject a combination of topoisomerase inhibitor and PARP inhibitor. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase and a topoisomerase, as well as providing formulations and modes of administering such compositions. | 2009-06-11 |
20090149398 | 6,11-3c-bicyclic 8a-azalide derivatives - Compounds of Formula (I), and pharmaceutically acceptable salts, esters, and prodrugs thereof: (I) are disclosed, wherein A, B, D, L, X, Y, Z and R | 2009-06-11 |
20090149399 | HETEROCYCLIC KINASE INHIBITORS - This invention relates to novel 2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide derivatives, and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by the inhibition of kinases including Src-kinase and Bcr-Abl kinase. | 2009-06-11 |
20090149400 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF - Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, | 2009-06-11 |
20090149401 | AMIDE AND PEPTIDE DERIVATIVES OF TETRAALKYLENEPENTAMINES AS TRANSFECTION AGENTS - This invention relates to newly identified pentamine based surfactant compounds, to the use of such compounds and to their production. The invention also relates to the use of the pentamine based compounds to facilitate the transfer of polynucleotides into cells. | 2009-06-11 |
20090149402 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER OR DIABETES - A pharmaceutical composition for treating cancer or diabetes which contains the following double-stranded RNA (A) or (B):
| 2009-06-11 |
20090149403 | siRNA silencing of genes expressed in cancer - The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression. | 2009-06-11 |
20090149404 | Oligonucleotide analogues and methods utilizing the same - A method for the prevention or treatment in a mammal of a disease preventable or treatable by the pharmacologically useful antisense or antigene activity of an oligonucleotide analogue or a pharmacologically acceptable salt thereof in the body of said mammal, which method comprises administering to said mammal in need of such prevention or treatment a pharmaceutically effective amount of an oligonucleotide analogue comprising two or more nucleoside units, wherein at least one of said nucleoside units is a structure of the formula (2): | 2009-06-11 |
20090149405 | Virus-like particle containing a Dengue virus recombinant replicon - The present invention relates virus-like particle vaccine containing dengue virus recombinant replicon as its core and its preparation method. Such vaccine can efficiently express antigen in the infected tells. Because dengue virus can infect dendritic cells, it can efficiently present antigen and has immunity effects. Further, different dengue virus types can be used to repeatedly produce efficient immune response, which strengthen body's immune response against the pathogen containing such antigen. Such vaccine can prevent and cure cancer and viral diseases. | 2009-06-11 |
20090149406 | Plasmid PXL3179 or NV1FGF - A prokaryotic recombinant host cell comprising a heterologous replication initiation protein that activates a conditional origin of replication and an extrachromosomal DNA molecule comprising a heterologous therapeutic gene and a conditional origin of replication whose functionality in the prokaryotic recombinant host cell requires a replication initiating protein which is foreign to the host cell is described. The host cell may comprise a pir gene having at least one mutation, which may occur in the pir gene copy number control region, the pir gene leucine zipper-like motif, or the pir gene DNA binding region. | 2009-06-11 |
20090149407 | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against beta-secretase (BACE), amyloid precursor protein (APP), pin-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1 and/or PS-2 expression or activity. | 2009-06-11 |
20090149408 | RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating telomerase gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of telomerase gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of telomerase genes, such as telomerase template RNA (TERC/TR), or a telomerase protein (TERT). | 2009-06-11 |
20090149409 | Tetracycline-Regulated Adeno-Associated Viral (AAV) Vectors for Gene Delivery to the Nervous System - A vector and a method are provided for delivering a nucleic acid to a nervous system cell. The vector includes a first nucleic acid, a second nucleic acid, inverted terminal repeats of adeno-associated virus, and a tetracycline-off regulatable promoter system that includes a first promoter operably linked to the first nucleic acid and a second promoter operably linked to the second nucleic acid. The promoters drive expression in opposite directions and away from the inverted terminal repeats. The method includes providing a recombinant adeno-associated viral (rAAV) vector and administering the vector to a nervous system cell. Expression of a product from the first nucleic acid is regulatable by the promoter system. | 2009-06-11 |
20090149410 | Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease - The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease. | 2009-06-11 |
20090149411 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH MODIFIED BASES AND METHODS OF USE THEREOF - Immunomodulatory oligonucleotide compositions are disclosed. These oligonucleotides comprise an immunostimulatory hexanucleotide sequence comprising a modified cytosine. These oligonucleotides can be administered in conjunction with an immunomodulatory peptide or antigen. Methods of modulating an immune response upon administration of the oligonucleotide comprising a modified immunostimulatory sequence are also disclosed. | 2009-06-11 |
20090149412 | Method for Inhibition of Phospholamban Activity for the Treatment of Cardiac Disease and Heart Failure - The present invention provides a method for the treatment of heart failure through the use of small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sacroplasmic reticulum Ca | 2009-06-11 |
20090149413 | RORS as Modifiers of the p21 Pathway and Methods of Use - Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided. | 2009-06-11 |
20090149414 | rAAV EXPRESSION SYSTEMS AND COMPOSITIONS - Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells. | 2009-06-11 |
20090149415 | Compounds for modulating the glycolysis enzyme complex and/or the transaminase complex - The invention relates to compounds for modulating the glycolosis enzyme complex and the transaminase complex, to pharmaceutical compositions containing said compounds, and to the uses of said compounds for the production of pharmaceutical compositions for treating different diseases. | 2009-06-11 |
20090149416 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation - Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans. | 2009-06-11 |
20090149417 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors - The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions. | 2009-06-11 |
20090149418 | Antimicrobial preparations using polysaccharide gel from durian fruit-rind - A water-soluble polysaccharide gel having good gelling property and good antimicrobial activity was extracted from fruit-rind of durian ( | 2009-06-11 |
20090149419 | HYDRAZIDO DERIVATIVES OF HYALURONIC ACID - Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives. | 2009-06-11 |
20090149420 | NOVEL COMPOSITIONS AND USE THEREOF FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS - The present invention relates to novel compositions comprising magnolol and/or honokiol and chondroitin as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders. | 2009-06-11 |
20090149421 | GEL FORMATION OF POLYELECTROLYTE AQUEOUS SOLUTIONS BY THERMALLY INDUCED CHANGES IN IONIZATION STATE - There is disclosed aqueous solutions of polyelectrolytes that can be neutralized by increasing temperature, under suitable polyelectrolyte charge state conditions, in order to obtain a homogeneous gel. This can be achieved by adding an appropriate weak electrolyte to the polyelectrolyte so that an increase of temperature will lead to a spatially homogeneous neutralization of the polyelectrolyte via proton transfer between the polyelectrolyte and the weak electrolyte. The ability of such a system to be thermally sensitive and to gel upon heating relies on the temperature dependence of the ionization equilibrium for the two components. This thermally induced neutralization reduces electrostatic repulsion between polyelectrolyte molecules allowing the manifestation of attractive polyelectrolyte-polyelectrolyte hydrophobic interactions and hydrogen bonding that result in gel formation. These new kinds of thermo sensitive gels can be used for biomedical applications. | 2009-06-11 |
20090149422 | HEMOSTATIC MATERIAL - A hemostatic powder comprises a chitosan salt together with at least one medical surfactant. At least one inert material may optionally be included. The hemostatic powder may be incorporated into wound dressings. | 2009-06-11 |
20090149423 | USE FOR A VERY LOW MOLECULAR WEIGHT HEPARINS - The present invention relates to the use of heparin oligosaccharides having a molecular weight≦5050 Da and an anti-factor Xa activity≦80 IU/mg, or their sodium salts, for preparing a medicament for the prevention and treatment of osteoporosis and associated pathologies and for preparing a medicament effective for the prevention and treatment of cerebral ischemia and pathologies related thereto whose treatment necessitates drugs able to cross the blood-brain barrier. | 2009-06-11 |
20090149424 | HEPARIN CONJUGATES AND METHODS - Heparin conjugates and methods of making and use thereof are disclosed. An illustrative heparin conjugate includes a composition wherein a bile acid is bonded to heparin through the 3-carbon of the bile acid. A spacer may be interposed between the bile acid and the heparin. Another embodiment includes a targeting moiety bonded to the heparin-bile acid conjugate through a spacer. Another illustrative heparin conjugate includes heparin covalently bonded to a sulfonated moiety, such as a naphthalene trisulfonate residue. A method of treating cancer includes administering a heparin conjugate to an individual in need thereof. | 2009-06-11 |
20090149425 | Malononitrile compound as pesticides - The present invention provides a malononitrile compound represented by the formula (I): wherein any one of X | 2009-06-11 |
20090149426 | PROCESS FOR SYNTHESIZING SILVER-SILICA PARTICLES AND APPLICATIONS - Size-controlled immobilization of metal nano-clusters onto particles or nanoparticles is achieved using a polyol process. Polyol processing makes it possible to use thiol groups as a chemical protocol to functionalize the surface of particles, such as silica and polystyrene nanoparticles. Metal nano-clusters, such as silver, gold, platinum and palladium, nucleate and grow on the surface of the particles. The metal nano-clusters may be synthesized in a one-pot process from metal salts, nitrates, nitrites, sulfates, sulfites and the like. Any source of metal ions compatible with the polyol suspension and selected particles may be used. The size of immobilized metal nano-clusters may be controlled by additions of a poly(vinylpyrrolidone) or other polymer capable of regulating the metal ion reduction and nucleation process and by controlling concentration of metal ions, the nucleation and/or growth temperatures, and processing time. | 2009-06-11 |
20090149427 | PHARMACEUTICALLY ACCEPTABLE SALTS AND HYDRATES OF RISEDRONIC ACID - The present invention is concerned with new hydrated forms of risedronate salts, processes of preparing the new hydrated forms, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing the same. In particular, the present invention provides tri-sodium risedronate dihydrate. | 2009-06-11 |
20090149428 | Methods for Assessing the Predisposition or Susceptibility to COPD - This invention relates to novel associations between polymorphisms in the genes encoding the human Epithelial Na+ Channel (ENaC) and COPD. More particularly, the invention relates to a method for assessing the predisposition and/or susceptibility of an individual to COPD, which method comprises detecting the presence of a polymorphism in one or more human ENaC-encoding genes, in particular position | 2009-06-11 |
20090149429 | ANTIVIRAL COMPOUNDS - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. | 2009-06-11 |
20090149430 | COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT - The present invention relates to a composition containing at least one amidine derivative or carboxamide derivative of general formula (I) or (A) in combination with at least one compound chosen from steroids, corticoids or corticosteroids, wherein said composition is suitable for the preparation of a medicament. | 2009-06-11 |
20090149431 | Eplerenone Drug Substance Having High Phase Purity - A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone. | 2009-06-11 |
20090149432 | METHODS FOR ADMINISTERING CORTICOSTEROID FORMULATIONS - Described here are methods for the treatment of respiratory conditions using nebulized corticosteroids. The methods administer a dose of corticosteroid twice a day or more with nebulization times of 5 minutes or less. The faster nebulization times improve patient compliance. The methods also employ a lower corticosteroid dose while achieving therapeutic efficacy similar to commercially available formulations. This results in improved patient safety by reducing the systemic exposure of the corticosteroid. | 2009-06-11 |
20090149433 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 2009-06-11 |
20090149434 | FORMULATIONS WITH IMPROVED BIOAVAILABILITY, COMPRISING A STEROID DERIVATIVE AND A POLYGLYCOLYSED GLYCERIDE - Compositions comprising a polyglycolysed glyceride, such as GELUCIRE, and a steroid related compound are provided. | 2009-06-11 |
20090149435 | PROCESS FOR MAKING A PHARMACEUTICAL COMPOSITION - Process for making a sterile, injectable pharmaceutical composition by combining triamcinolone, a buffer and a high viscosity hyaluronate. | 2009-06-11 |
20090149436 | CASPASE INHIBITOR - The present invention provides a caspase inhibitor containing a cobalt porphyrin complex compound or cobalt choline complex compound as an active ingredient. The caspase inhibitor of the present invention can strongly and specifically inhibit the caspase activity. In addition, the caspase inhibitor/cobalt porphyrin complex compound or cobalt choline complex compound of the present invention is useful as a pharmaceutical agent for the prophylaxis or treatment of various diseases relating to apoptosis. | 2009-06-11 |
20090149437 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 2009-06-11 |
20090149438 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 2009-06-11 |
20090149439 | PYRIDYLMETHYSULFONE DERIVATIVE - The present invention relates to a novel compound having an effect of inhibiting production/secretion of β-amyloid protein. The present invention provides a compound represented by the general formula (1): | 2009-06-11 |
20090149440 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF - The present invention provides an agent which exhibits excellent antibacterial activity, low toxicity, improved bioavailability, and low binding rate to serum proteins. The present invention is directed to a pyridonecarboxylic acid derivative represented by formula (1): | 2009-06-11 |
20090149441 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The present invention is related to a compound of formula (I): | 2009-06-11 |
20090149442 | Atypical antipsychotic agents having low affinity for the D2 receptor - The present invention provides novel compounds of Formula I: | 2009-06-11 |
20090149443 | P38 INHIBITORS AND METHODS OF USE THEREOF - Compounds of formula (I): in which A, B, X, Ar | 2009-06-11 |
20090149444 | Benzylamine analogues - A compound of the formula (I): | 2009-06-11 |
20090149445 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS - The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: | 2009-06-11 |
20090149446 | Compositions Comprising Nicotinic Agonists and Methods of Using Same - The disclosure is directed at least in part to compositions and methods comprising nicotinic agonists for treating e.g., nervous system disorders, in particular, to combination therapies that include a nicotinic agonist (for example, nicotine) and a nicotinic acetylcholine receptor desensitization inhibitor (for example, opipramol). | 2009-06-11 |
20090149447 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | 2009-06-11 |
20090149448 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases - The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation. | 2009-06-11 |
20090149449 | PYRROLOBENZODIAZEPINE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME AND METHODS RELATED THERETO - Disclosed are compounds of Formula I | 2009-06-11 |
20090149450 | SUBSTITUTED IMIDAZOHETEROCYCLES - The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I | 2009-06-11 |
20090149451 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain potassium ATP (K | 2009-06-11 |
20090149452 | XANTHINE OXIDASE INHIBITOR - A compound represented by the following formula (I) is used as a xanthine oxidase inhibitor: in which R | 2009-06-11 |
20090149453 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS AND DISEASES ASSOCIATED THEREWITH - The invention features methods and compositions for treating bacterial infections. | 2009-06-11 |
20090149454 | Benzomorpholine derivatives and methods of use - Selected benzomorpholine compounds are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2009-06-11 |
20090149455 | Use of Triazolopyrimidines for Controlling Plant Diseases on Legumes - The triazolopyrimidines of the general formula (I) | 2009-06-11 |
20090149456 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors - The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents. | 2009-06-11 |
20090149457 | 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors - There are provided thieno[2,3-c]pyrazole derivatives of formula (I), wherein A is an aryl or heteroaryl ring, on which the substituent-NHZR | 2009-06-11 |
20090149458 | PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS - A pyrrolo[3,2-d]pyrimidine compound, such as a compound of the formula (I): | 2009-06-11 |
20090149459 | P38 INHIBITORS AND METHODS OF USE THEREOF - This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38. | 2009-06-11 |
20090149460 | New Compounds - The present invention provides new compounds of formula Ia and Ib: | 2009-06-11 |
20090149461 | METHOD OF TREATING CANCER - Methods of treating cancer using N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide are disclosed. | 2009-06-11 |
20090149462 | PROCESS FOR PURIFICATION OF APREPITANT - The present invention relates to a process for obtaining pure aprepitant substantially free of undesired diastereomeric isomer, namely 5-[2(S)-[1(RS)-[3,5-bis(trifluoromethyl)-phenyl)ethoxy]-3-(S)-(4-fluorophenyl)-morpholin-4-yl-methyl]-3,4-dihydro-2H-1,2,4-triazol-3-one. The present invention further provides an improved process for preparation of aprepitant crystalline form II. The present invention also relates to novel amorphous form of aprepitant, a process for its preparation and to a pharmaceutical composition comprising it. The present invention further relates to aprepitant having a mean particle size of less than about 11.5 microns, a process for its preparation and to a pharmaceutical composition comprising it. Thus, for example, aprepitant having a content of diastereomeric impurity of 1.1% is dissolved in ethyl acetate at 70° C., the solution is concentrated to half the initial volume by distilling off ethyl acetate, and the resulting solid is collected at 0-5° C. to give pure aprepitant substantially free of its diastereomeric impurity. | 2009-06-11 |
20090149463 | Therapeutic agents - The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them. | 2009-06-11 |
20090149464 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases - Use of 1,4-bis(3-aminoalkyl)piperazine derivatives as defined in formula I or II for the manufacture of a pharmaceutical composition intended for the treatment of neurodegenerative diseases, related neurodegenerative diseases, developmental diseases or cancer. The instant invention is also directed to some specific 1,4-bis(3-aminoalkyl)piperazine derivatives and pharmaceutical composition including them. | 2009-06-11 |
20090149466 | INHIBITORS OF STEAROYL-COA DESATURASE - Provided herein are compounds of the formula (I): | 2009-06-11 |
20090149467 | Tyrosine Kinase Inhibitors - The present invention relates to pyridinyloxy- and pyrimidinyloxyindole derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 2009-06-11 |
20090149468 | Substituted heterocyclic compounds and methods of use - The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. host diseases, T-cell mediated hypersensitivity diseases, contact hypersensitivity, delayed-type hypersensitivity, gluten-sensitive enteropathy, Type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Graves' Disease, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, autoimmune diseases, glomerulonephritis, serum sickness, uticaria, respiratory allergies, asthma, hayfever, allergic rhinitis, skin allergies, scleracielma, mycosis fungoides, acute inflammatory responses, acute respiratory distress syndrome, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, Type II diabetes and cancers where PKC theta or other PKC-family kinases are activated, overexpressed or facilitate tumor growth or survival of tumor cells, T cell leukemia, thymoma, T and B cell lymphoma, colon carcinoma, breast carcinoma and lung carcinoma or provides resistance to chemotherapeutic drugs. | 2009-06-11 |
20090149469 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors - The present invention relates to a compound of formula I | 2009-06-11 |
20090149470 | Novel aminopyridine derivatives having aurora a selective inhibitory action - The present invention relates to a compound represented by the general formula (I): | 2009-06-11 |
20090149471 | Monocyclic Heterocyclic Compounds - This invention relates to compounds of the general formula: | 2009-06-11 |
20090149472 | SALTS OF SUBSTITUTTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AND MEDICAMENTS - The present invention relates to salts of substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. | 2009-06-11 |
20090149473 | Topical antifungal composition - A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content of less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of a patient requiring such treatment an antifungal composition. | 2009-06-11 |
20090149474 | GABA-B RECEPTOR MODULATORS - The present invention relates to novel imidazole derivatives having a positive allosteric GABA | 2009-06-11 |
20090149475 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO - There are disclosed novel compounds of Formula (I) wherein L, R | 2009-06-11 |
20090149476 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same - A subject of the invention is the compounds of formula (I): | 2009-06-11 |
20090149477 | 4,5-DIPHENYL-PYRIMIDINYL SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS - This invention relates to a compound of formula I, | 2009-06-11 |